

PRESS RELEASE

30 April 2025 08:00:00 CEST

Change in number of shares and votes in Saniona AB

During April, the registered number of shares and votes in Saniona AB ("Saniona") has increased due to the exercise of warrants series TO 4 issued in the rights issue of units resolved by the board of directors on 14 December 2023 and approved by the extraordinary general meeting on 16 January 2024, as well as the directed issue of shares to those who had entered into top-down guarantee commitments to secure the last part of the subscription of the exercise of warrants series TO 4. As of 30 April 2025, the registered number of shares and votes in Saniona amounts to 136,088,387.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-04-30 08:00 CEST.

Attachments

Change in number of shares and votes in Saniona AB